Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia

Abstract

Until 1983, results of treatment of acute myelogenous leukemia (AML) in Poland with different regimens were very poor. In 1983, the Polish Pediatric Leukemia/Lymphoma Study Group introduced a unified treatment protocol – a modified version of BFM-83 protocol. This led to an increase in the curability of AML from 15% to approximately 32%. In 1994, a modification was made: the high-risk patients (>5% blasts in bone marrow on day 15 of therapy and all M5 cases) received two additional cycles with intermediate-dose cytarabine (ID-ARAC). This led to a nonsignificant improvement in the 5-year event-free survival (EFS) rate from 32 to 36%. A new treatment protocol employing idarubicin in place of daunorubicin was introduced in 1998 and produced better initial responses, increase in the number of patients attaining remission after induction therapy and proportional increase of standard-risk patients.The probability of 5-year EFS (pEFS) for the whole group of patients increased from 36 to 47%. In standard- and high-risk groups, the 5-year pEFS was 62 and 33%, respectively. The probability of 5-year disease-free survival was 58% in the whole group, and there were no differences between risk groups. Unsatisfactory treatment results in children classified into the high-risk group are principally due to the low remission rate.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Cyklis R, Armata J, Dluzniewska A, Boguslawska-Jaworska J, Pejcz J, Wolak D et al. The results of therapy of the acute myeloblastic leukemia in childhood with AML-BFM-83 regimen in the material of the Polish Group on Therapy of Leukemia in Childhood Preliminary report. Pol Tyg Lek 1988; 43: 376–379.

    CAS  PubMed  Google Scholar 

  2. Cyklis R, Dluzniewska A, Armata J, Boguslawska -Jaworska J, Ochocka M, Januszkiewicz-Lewandowska D et al. Efficacy of AML-BFM-83 regimen in children with acute myeloblastic leukemia. Over 10 year experience of Polish Pediatric Leukemia/Lymphoma Study Group. Acta Hematol Pol 1996; 27: 131–137.

    Google Scholar 

  3. Dluzniewska A, Balwierz W, Moryl-Bujakowska A, Boguslawska-Jaworska J, Dobaczewski G, Januszkiewicz-Lewandowska D et al. Intermediate doses of cytarabine arabinoside in the treatment of acute non- lymphoblastic leukemia in children. Medycyna Wieku Rozwojowego 2000; 4 (Suppl 2): 33–41.

    CAS  PubMed  Google Scholar 

  4. Dluzniewska A, Balwierz W, Balcerska A, Chybicka A, Dobaczewski G, Kowalczyk J et al. Efficacy of idarubicin in the treatment of childhood acute non lymphoblastic leukemia – report of Polish Pediatric Leukemia/Lymphoma Study Group. Przegl Lek 2003; 60 (Suppl 5): 17–21.

    PubMed  Google Scholar 

  5. Creutzig U, Ritter J, Schellong G . Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990; 75: 1932–1940.

    CAS  PubMed  Google Scholar 

  6. Creutzig U, Körholz D, Niemeyer CM, Kabisch H, Graf N, Reiter A et al. Toxicity and effectivity of high dose idarubicin during AML induction therapy: Results of a pilot study in children. Klin Pädiatr 2000; 212: 163–168.

    Article  CAS  Google Scholar 

  7. Carella AM, Berman E, Maraone MP, Ganzina F . Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica 1990; 75: 159–169.

    CAS  PubMed  Google Scholar 

  8. Mehta J, Powles R, Singhal S, Horton C, Hambin M, Zomas A et al. Idarubicin, high dose cytarabine and etoposide for induction of remission in acute leukaemia. Semin Hematol 1996; 33 (Suppl 3): 18–23.

    CAS  PubMed  Google Scholar 

  9. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Blütters-Sawatzki R, et al., for the AML-BFM Study Group. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001; 15: 348–354.

    Article  CAS  Google Scholar 

  10. Hurwitz CA, Mounce KG, Grier HE . Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol 1995; 17: 185–197.

    Article  CAS  Google Scholar 

  11. Reiffers J, Huguet F, Stoppa AM . A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389–395.

    CAS  PubMed  Google Scholar 

  12. Wells RJ, Arndt CA . New agents for treatment of children with acute myelogenous leukemia. J Pediatr Hematol Oncol 1995; 17: 225–233.

    Article  CAS  Google Scholar 

  13. Campbell MJ, Machin D . Medical Statistics A Commonsense Approach. Chichester: John Wiley and Sons, 1990.

    Google Scholar 

  14. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al., for the AML-BFM Study Group. Improved treatment results in high risk pediatric AML patients after intensification with high dose Ara-C and mitoxantrone: results of study AML-BFM 93. J Clin Oncol 2001; 19: 2705–2713.

    Article  CAS  Google Scholar 

  15. Katano N, Tsurusawa M, Hirota T, Horikoshi Y, Mimaya J, Yanai M et al. Treatment outcome and prognostic factors in childhood acute myeloblastic leukemia: a report from the Japanese Children's Cancer and Leukemia Study Group (CCLSG). Int J Hematol 1997; 66: 103–110.

    Article  CAS  Google Scholar 

  16. Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood 2001; 98: 3589–3594.

    Article  CAS  Google Scholar 

  17. Lie SO, Jonmundsson G, Mellander L, Siimes SA, Yssing M, Gustafsson G . A population based study of 272 children with acute myeloid leukemia treated on two consecutive protocols with different intensity: best outcome in girls, infants and children with Down's syndrome, Nordic Society of Pediatric Hematology and Oncology. Br J Haematol 1996; 94: 82–88.

    Article  CAS  Google Scholar 

  18. Hann IM, Stevens FR, Goldstone AH, Rees JK, Wheatley K, Gray RG . Randomized comparison of DAT versus ADE induction therapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Councils 10th AML trial (MRCAML10). Adult and Childhood Leukemia Working Parties of the Medical Research Council. Blood 1997; 89: 2311–2318.

    CAS  PubMed  Google Scholar 

  19. Stevens RF, Hann IM, Wheatley K, Gray RG, on behalf of the MRC Childhood Leukemia Working Party. Marked improvements in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998; 101: 130–140.

    Article  CAS  Google Scholar 

  20. Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003; 17: 515–527.

    Article  CAS  Google Scholar 

  21. Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH et al. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia 2003; 17: 883–886.

    Article  CAS  Google Scholar 

  22. Loh ML, Reynolds MG, Vattikuti S, Gerbing RB, Alonzo TA, Carlson E et al. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia 2004; 18: 1831–1834.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Investigators of the study: A Moryl-Bujakowska, M Mikolajczyk, W Strojny, T Klekawka, Department of Pediatric Oncology/Hematology, Polish-American Institute of Pediatrics, Jagiellonian University, Krakow; M Stefaniak, U Malek, Department of Pediatric Hematology/Oncology, Medical Academy, Lublin; K Krenke, A Malinowska, Department of Pediatrics, Hematology and Oncology, Medical Academy, Warsaw; R. Tomaszewska, Department of Pediatric Hematology and Chemotherapy, Silesian Medical Academy, Zabrze; D Januszewska-Lewandowska, L Lewandowska, Department of Pediatric Hematology/Oncology, Medical Academy, Poznan; G Dobaczewski, Department of Pediatric Hematology/Oncology, Medical Academy, Wroclaw; J Styczynski, Department of Pediatrics, Hematology and Oncology, Medical Academy, Bydgoszcz; J Niedzwiedzki, Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical Academy, Gdansk

Statistician: H Stanuch, Department of Biostatistics Jagiellonian University, Krakow.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to A Dluzniewska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dluzniewska, A., Balwierz, W., Armata, J. et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 19, 2117–2124 (2005). https://doi.org/10.1038/sj.leu.2403892

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403892

Keywords

This article is cited by

Search

Quick links